在15年分析中，延长ET未显示OS获益。如今，辅助治疗abema和ribo均取得了阳性OS结果。您认为在辅助CDK4/6i治疗后，延长ET是否仍有作用？
#ESMO26 #ESMOAmbassadors @myESMO
835 浏览 · 4 赞 · 1 转发 · 5 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- Michiel Strijbos@StrijbosMichiel
@Rodrosb @myESMO Where did you see the ribo OS benefit???
- Gabriel Lazcano@gv_lazcano
@Rodrosb @myESMO Wrong question, as CDK4/6i shouldn't be considered SoC for adjuvancy. I'm gonna die on that hill. Let's no justify financial toxicity based on marginal benefits and forced p-values. Our patients deserve better.
- Pablo Jara Martin@pablojaramartin
@Rodrosb @myESMO I see the benefit in high-risk, node-positive patients, especially after the NSABP B-42 data presented at #ESMO26. However, I have more doubts about the N0 population in NATALEE. Great topic!@Rodrosb
- Paula Cabrera@anelcabrera
@Rodrosb @myESMO And what if the control arm of CDK4-6i is not the best??
- Rodrigo Sánchez-Bayona@Rodrosb
@anelcabrera @PabloMando @matteolambe @E_de_Azambuja @PTarantinoMD
来源：Rodrigo Sánchez-Bayona · x.com